Propanc targets early November for final PRP clinical protocol
Propanc Biopharma said the final clinical protocol for PRP is targeted for early November 2026.
Related stories
DoorDash Q3 Revenue Reaches $4.616 Billion, Net Income $466 Million
DoorDash Q3 revenue was $4.616 billion, versus an IBES estimate of $4.564 billion. Net income was $466 million, compared with an IBES estimate of $388.8 million.
M impact | EQUITY | Oct 29, 2026, 11:23 AM UTC
Entegris Q3 Profit Rises to $157.8 Million
Entegris reported third-quarter profit of $157.8 million, or $1.03 per share, compared with $70.5 million, or $0.46 per share, a year earlier.
M impact | EQUITY | Oct 29, 2026, 11:22 AM UTC
Blue Star Q2 profit rises 25.5% to ₹123.92 crore, beating poll estimate
Blue Star reported consolidated profit attributable to owners of ₹123.92 crore for Q2 FY27, up 25.5% year on year and above the CNBC-TV18 poll estimate of ₹70 crore. Revenue from o
M impact | EQUITY | Oct 29, 2026, 11:22 AM UTC
Ligand Pharmaceuticals Swings to Q3 Net Loss of $28.49 Million
Ligand Pharmaceuticals reported a net loss of $28.49 million in Q3, compared with a profit a year earlier.
M impact | EQUITY | Oct 29, 2026, 11:22 AM UTC
Kymera Q3 Net Loss Widens as R&D Costs Rise
M impact | EQUITY | Oct 29, 2026, 11:22 AM UTC
First Mid Bancshares Q3 Profit Tops Estimates on Deposit Growth
M impact | EQUITY | Oct 29, 2026, 11:22 AM UTC